Rapacuronium: premarket drug evaluation can be very effective for the identification of drug risks.
Lim
Robyn
R
D001986:Bronchial Spasm / Q000139:chemically induced / Q000453:epidemiology / Q000503:physiopathology; D006801:Humans; D003473:Neuromuscular Nondepolarizing Agents / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration; D014673:Vecuronium Bromide / Q000009:adverse effects* / Q000031:analogs & derivatives*
D003473:Neuromuscular Nondepolarizing Agents; D014673:Vecuronium Bromide; C082938:rapacuronium